Novartis Needs Special Delivery for Potent Cell Therapy
This article is for subscribers only.
Novartis AG has a promising therapy for cancer. It’s just not sure how to get it to patients easily.
The treatment is so potent that it cleared malignant cells in about 90 percent of patients facing almost certain death from the most common form of cancer in children.